Biosimilars Stakeholder Summit: Interchangeable Biosimilars in Inflammatory Diseases

Maia Kayal, MD, MS, and Jonathan Kay, MD, provide a clinical overview of inflammatory diseases and describe comorbid conditions typically seen in patients.

Experts discuss the humanistic and economic impacts that affect patients with inflammatory diseases.

A panel of experts review the key drivers contributing to the economic impact of inflammatory diseases in the United States.

Maia Kayal, MD, MS, provides an overview of the biologics used in inflammatory diseases.

Jonathan Kay, MD, reviews the barriers related to access to biologics such as economic barriers, health inequities, or disparities.

Jonathan Kay, MD, and Kimberly C. Chen DO, MSHLM, define what a biosimilar is and discuss the potential for a lower cost than the reference product.

Maia Kayal, MD, MS, and Kimberly C. Chen DO, MSHLM, discuss opportunities that biosimilars provide for inflammatory conditions from both a payer and provider perspective.

Jonathan Kay, MD, discusses challenges that patients may experience related to biosimilars for inflammatory conditions

Kimberly C. Chen DO, MSHLM, and Maia Kayal, MD, MS, review the challenges related to biosimilars from the payer perspective and strategies payers may employ to help improve the uptake of biosimilars.

Jonathan Kay, MD, provides an overview of the existing FDA-approved biosimilars for adalimumab.

Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study.

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options.

Kimberly C. Chen, DO, MSHLM, discusses the potential benefits of interchangeable biosimilars to patients and payers.

Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy.

Jonathan Kay, MD, and Kimberly C. Chen, DO, MSHLM, discuss clinical and financial concerns related to automatic substitution at the pharmacy for an interchangeable biosimilar from a payer perspective.

Experts review best practices around plan design that payers and plan sponsors should address as more interchangeable biosimilars potentially enter the market.

A panel of experts discuss future opportunities with interchangeable biosimilars from payer and provider perspectives.